ELTX on Nasdaq
Elicio Therapeutics, Inc.
American pharmaceutical preparations company based in Boston. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Apricus Biosciences, GeoVax Labs, Inc. or Korsana Biosciences, Inc., or pick any stock.
- TickerELTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersBoston, Massachusetts1
- Incorporated inDE2
- Business address451 D Street, 5Th Floor, Boston, Ma 022102
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate robust T cell responses in patients that can potentially translat…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development83¢$18.1M
- Interest17¢$3.6M
Out of $2.3M in revenue.54 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $24.9M | $33.7M |
| General and administrative | $12.8M | $11.3M |
| Total operating expenses | $37.7M | $45.0M |
| Loss from operations | -$37.7M | -$45.0M |
| Change in fair value of warrant liabilities | -$1.9M | -$3.9M |
| Loss on issuance of pre-funded warrants | $0 | -$3.5M |
| Gain on sale of equipment | $0 | $3.0K |
| Foreign exchange transaction gain | $0 | $151.0K |
| Grant income | $415.0K | $0 |
| Interest income | $776.0K | $777.0K |
| Interest expense | -$1.1M | -$455.0K |
| Total other expense, net | -$1.9M | -$6.9M |
| Provision for income taxes | $0 | $0 |
| Net loss | -$39.6M | -$51.9M |
| Foreign currency translation adjustment | $48.0K | $22.0K |
| Comprehensive loss | -$39.5M | -$51.9M |
| Net loss per common share, basic (in dollars per share) | -$2.58 | -$4.25 |
| Net loss per common share, diluted (in dollars per share) | -$2.58 | -$4.25 |
| Weighted average common shares outstanding, basic (in shares) | 15.3M shares | 12.2M shares |
| Weighted average common shares outstanding, diluted (in shares) | 15.3M shares | 12.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $18.6M | $17.6M | |
| Restricted cash, current | $0 | $1.2M | |
| Prepaid expenses and other current assets | $748.0K | $1.9M | |
| Total current assets | $19.3M | $20.7M | |
| Property and equipment, net | $295.0K | $483.0K | |
| Operating lease, right-of-use assets | $4.8M | $5.7M | |
| Restricted cash, noncurrent | $704.0K | $696.0K | |
| Other long-term prepaid assets | $770.0K | $600.0K | |
| Total assets | $25.9M | $28.2M | |
| Accounts payable | $672.0K | $1.0M | |
| Accrued expenses | $6.4M | $8.4M | |
| Deferred research obligation | $0 | $1.2M | |
| Operating lease liability, current | $1.0M | $901.0K | |
| Total current liabilities | $8.1M | $11.5M | |
| Warrant liabilities | $2.6M | $2.8M | |
| Operating lease liability, noncurrent | $4.1M | $5.1M | |
| Long-term debt, net | $9.4M | $20.0M | |
| Total liabilities | $24.2M | $39.5M | |
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.01 par value; 300,000,000 shares authorized; 17,814,762 and 11,043,837 shares issued at December 31, 2025 and 2024, respectively; 17,800,307 and 11,029,382 shares outstanding as of December 31, 2025 and 2024, respectively | $178.0K | $110.0K | |
| Treasury stock, at cost, 14,455 shares outstanding | -$150.0K | -$150.0K | |
| Additional paid-in capital | $235.4M | $183.0M | |
| Accumulated other comprehensive loss | -$127.0K | -$175.0K | |
| Accumulated deficit | -$233.7M | -$194.1M | |
| Total stockholders' equity (deficit) | $1.6M | -$11.3M | $11.4M |
| Total liabilities, convertible preferred stock, and stockholders equity (deficit) | $25.9M | $28.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 17.8M shares | 11.0M shares | |
| Common stock, shares outstanding (in shares) | 17.8M shares | 11.0M shares | |
| Treasury stock, shares outstanding (in shares) | 14.5K shares | 14.5K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $18.6M | $17.6M | |
| Restricted cash, current | $0 | $1.2M | |
| Prepaid expenses and other current assets | $748.0K | $1.9M | |
| Total current assets | $19.3M | $20.7M | |
| Property and equipment, net | $295.0K | $483.0K | |
| Operating lease, right-of-use assets | $4.8M | $5.7M | |
| Restricted cash, noncurrent | $704.0K | $696.0K | |
| Other long-term prepaid assets | $770.0K | $600.0K | |
| Total assets | $25.9M | $28.2M | |
| Accounts payable | $672.0K | $1.0M | |
| Accrued expenses | $6.4M | $8.4M | |
| Deferred research obligation | $0 | $1.2M | |
| Operating lease liability, current | $1.0M | $901.0K | |
| Total current liabilities | $8.1M | $11.5M | |
| Warrant liabilities | $2.6M | $2.8M | |
| Operating lease liability, noncurrent | $4.1M | $5.1M | |
| Long-term debt, net | $9.4M | $20.0M | |
| Total liabilities | $24.2M | $39.5M | |
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.01 par value; 300,000,000 shares authorized; 17,814,762 and 11,043,837 shares issued at December 31, 2025 and 2024, respectively; 17,800,307 and 11,029,382 shares outstanding as of December 31, 2025 and 2024, respectively | $178.0K | $110.0K | |
| Treasury stock, at cost, 14,455 shares outstanding | -$150.0K | -$150.0K | |
| Additional paid-in capital | $235.4M | $183.0M | |
| Accumulated other comprehensive loss | -$127.0K | -$175.0K | |
| Accumulated deficit | -$233.7M | -$194.1M | |
| Total stockholders' equity (deficit) | $1.6M | -$11.3M | $11.4M |
| Total liabilities, convertible preferred stock, and stockholders equity (deficit) | $25.9M | $28.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 17.8M shares | 11.0M shares | |
| Common stock, shares outstanding (in shares) | 17.8M shares | 11.0M shares | |
| Treasury stock, shares outstanding (in shares) | 14.5K shares | 14.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$39.6M | -$51.9M |
| Depreciation | $204.0K | $321.0K |
| Amortization of right-of-use assets, operating leases | $924.0K | $857.0K |
| Amortization of debt discount | $217.0K | $75.0K |
| Non-cash interest expense | $107.0K | $232.0K |
| Costs expensed upon the issuance of warrants | $0 | $549.0K |
| Change in fair value of warrant liabilities | $1.9M | $3.9M |
| Loss on issuance of warrants | $0 | $3.5M |
| Stock-based compensation | $2.7M | $1.5M |
| Gain on disposal of property and equipment | $0 | -$3.0K |
| Prepaid expenses and other current assets | $1.1M | $835.0K |
| Other long-term prepaid assets | -$170.0K | $2.2M |
| Accounts payable | -$366.0K | -$3.3M |
| Accrued expenses | -$2.0M | $4.7M |
| Deferred research obligation | -$1.2M | $475.0K |
| Operating lease liability | -$901.0K | -$911.0K |
| Net cash used in operating activities | -$37.0M | -$37.1M |
| Purchases of property and equipment | -$16.0K | -$87.0K |
| Proceeds from sale of property and equipment | $0 | $3.0K |
| Net cash used in investing activities | -$16.0K | -$84.0K |
| Proceeds from the exercise of common stock warrants | $1.3M | $0 |
| Proceeds from June 2025 Promissory Note, net of issuance costs | $9.9M | $0 |
| Proceeds from issuance of common stock warrants from March 2024 Offering | $0 | $6.0M |
| Proceeds from issuance of common stock warrants from July 2024 Public Offering | $0 | $11.5M |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs. | $16.2M | $4.6M |
| Proceeds from issuance of common stock from July 2024 Public Offering | $0 | $1.1M |
| Payment of warrant issuance costs | $0 | -$549.0K |
| Proceeds from issuance of Convertible Note, net of issuance costs | $0 | $19.7M |
| Proceeds from issuance of common stock and common warrants from January 2025 Offering | $9.1M | $0 |
| Proceeds from exercise of stock options | $149.0K | $39.0K |
| Net cash provided by financing activities | $36.7M | $42.3M |
| Effect of foreign currency on cash | $48.0K | $22.0K |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$225.0K | $5.2M |
| Fair value of pre-funded warrants at issuance date | $0 | $13.4M |
| Fair value of common warrants at issuance date | $0 | $6.5M |
| Fair value of common warrants upon settlement | $2.1M | $0 |
| Accretion of promissory note to face value | $0 | $26.0K |
| Fair value of common warrants issued with January 2025 Offering | $9.7M | $0 |
| Fair value of common warrants issued with June 2025 Promissory Note | $641.0K | $0 |
| Non-cash vesting of restricted common stock | $0 | $25.0K |
| Conversion of related-party senior note and interest into common stock | $20.2M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Elicio Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerRobert Connelly Jun 7, 2023 to now11
- PresidentRobert Connelly Jun 7, 2023 to now11
- Chief financial officerBrian Piekos Jun 5, 2023 to Feb 5, 202412
Board members and other officers (20)
- OfficerPreetam Shah Apr 2, 2025 to now13
- Chief Business OfficerAnnette Matthies Jun 7, 2023 to Jun 7, 202314
- Chief Scientific OfficerPeter Demuth Jun 7, 2023 to now15
- OfficerChristopher Haqq Jun 12, 2023 to now16
- OfficerGregory S. Curhan Feb 4, 2021 to Mar 4, 202217
- OfficerItzhak Goldberg Feb 4, 2021 to Dec 7, 202118
- OfficerJay Venkatesan Feb 4, 2021 to May 27, 202219
- OfficerJennifer J. Rhodes Feb 4, 2021 to Mar 4, 202220
- OfficerJohn F. Neylan Feb 4, 2021 to Mar 4, 202221
- Board memberAssaf Segal Jun 7, 2023 to Jun 7, 202322
- Board memberCarol Gail Ashe Jun 7, 2023 to now23
- Board memberJulian Adams Jun 7, 2023 to now24
- Board memberRobert Connelly Jun 7, 2023 to now11
- Board memberRobert R. Ruffolo Jun 7, 2023 to now25
- Board memberYekaterina Chudnovsky Jun 12, 2023 to now26
- Board memberAllen Nissenson Feb 4, 2021 to now27
- Board memberJay Venkatesan Feb 4, 2021 to now19
- Board memberKaren J. Wilson Feb 4, 2021 to now28
- Board memberVictor F. Ganzi Feb 4, 2021 to Jun 13, 202229
- Board memberItzhak Goldberg Dec 3, 2021 to Jul 11, 202230
Former names
- Angion Biomedica Corp.Mar 4, 2014 to May 30, 20232
Timeline
- Jun 7, 2023New chief executive Robert Connelly becomes CEO11
Filings
296 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 73 major events, 98 insider forms, 28 large holders, 2 private raises, 72 other. The latest 20:
- Oct 9, 2026DEF 14A EDGAR
- Sep 14, 20268-K EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 16, 2026SCHEDULE 13G EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jul 2, 2026424B5 EDGAR
- Jul 2, 20268-K EDGAR
- Jun 24, 20268-K EDGAR
The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 13 buys and 12 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 22, 2023 | GKCC, LLC10% owner | Buy | 1,213,000 | $5.81 | $7.0M | Form 4 |
| May 25, 2022 | Venkatesan JayDirector | Buy | 11,313 | $1.25 | $14.1K | Form 4 |
| May 24, 2022 | Venkatesan JayDirector | Buy | 32,200 | $1.24 | $39.9K | Form 4 |
| May 20, 2022 | Nissenson AllenDirector | Buy | 2,037 | $1.18 | $2.4K | Form 4 |
| May 20, 2022 | Venkatesan JayDirector | Buy | 50,000 | $1.23 | $61.5K | Form 4 |
| May 19, 2022 | Nissenson AllenDirector | Buy | 7,346 | $1.16 | $8.5K | Form 4 |
| Dec 28, 2021 | Venkatesan JayDirector | Buy | 210,337 | $2.66 | $559.5K | Form 4 |
| Dec 27, 2021 | Venkatesan JayDirector | Buy | 66,907 | $2.55 | $170.6K | Form 4 |
| Dec 20, 2021 | Venkatesan JayDirector | Buy | 3,527 | $2.54 | $9.0K | Form 4 |
| Dec 20, 2021 | Neylan John F.See Remarks | Sale | 358 | $2.62 | $938 | Form 4 |
| Dec 17, 2021 | Venkatesan JayDirector | Buy | 13,742 | $2.54 | $34.9K | Form 4 |
| Dec 16, 2021 | Venkatesan JayDirector | Buy | 27,883 | $2.55 | $71.1K | Form 4 |
| Dec 15, 2021 | Venkatesan JayDirector | Buy | 77,604 | $2.41 | $187.0K | Form 4 |
| Dec 15, 2021 | CURHAN GREGORY SSee Remarks | Buy | 4,000 | $2.37 | $9.5K | Form 4 |
| Dec 14, 2021 | Rhodes Jennifer JSee Remarks | Sale | 451 | $2.42 | $1.1K | Form 4 |
| Dec 6, 2021 | Goldberg ItzhakDirector | Sale | 32,118 | $3.35 | $107.6K | Form 4 |
| Dec 3, 2021 | Goldberg ItzhakDirector | Sale | 40,215 | $3.39 | $136.3K | Form 4 |
| Dec 2, 2021 | Goldberg ItzhakDirector | Sale | 38,800 | $3.51 | $136.2K | Form 4 |
| Dec 1, 2021 | Goldberg ItzhakDirector | Sale | 38,867 | $3.54 | $137.6K | Form 4 |
| Nov 18, 2021 | Neylan John F.See Remarks | Sale | 374 | $4.13 | $1.5K | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Moti Investments LLCSCHEDULE 13G, 1 filing Jul 16, 202631
- Knoll Capital Management, LLCSCHEDULE 13G/A, 2 filings Feb 5, 2025 to Jul 8, 202632
- Actyus Private Equity SGIIC, S.A.SCHEDULE 13G/A, 3 filings Jan 7, 2025 to Oct 7, 202533
- GKCC, LLCSCHEDULE 13D/A, 6 filings Jun 14, 2023 to Jun 4, 202534
- Yekaterina ChudnovskySCHEDULE 13D/A, 1 filing Mar 7, 202535
- Clal Biotechnology Industries Ltd.SC 13D/A, 5 filings Jun 12, 2023 to Apr 10, 202436
- Vifor (International) LtdSC 13G/A, 2 filings Mar 30, 2022 to Jul 7, 202337
- EISA-ABC LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202338
- Itzhak GoldbergSC 13G/A, 1 filing Feb 14, 202339
- Thomas A. Satterfield Jr.SC 13G/A, 2 filings May 19, 2022 to Feb 10, 202340
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 48. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARPreetam Shah, Officer
- 14
- 15
- 16SEC EDGARChristopher Haqq, Officer
- 17SEC EDGARGregory S. Curhan, Officer
- 18SEC EDGARItzhak Goldberg, Officer
- 19SEC EDGARJay Venkatesan, Officer
- 20SEC EDGARJennifer J. Rhodes, Officer
- 21SEC EDGARJohn F. Neylan, Officer
- 22SEC EDGARAssaf Segal, Board member
- 23SEC EDGARCarol Gail Ashe, Board member
- 24SEC EDGARJulian Adams, Board member
- 25SEC EDGARRobert R. Ruffolo, Board member
- 26SEC EDGARYekaterina Chudnovsky, Board member
- 27SEC EDGARAllen Nissenson, Board member
- 28SEC EDGARKaren J. Wilson, Board member
- 29SEC EDGARVictor F. Ganzi, Board member
- 30SEC EDGARItzhak Goldberg, Board member
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40